BerGenBio

Edison Investment Research is terminating coverage on BerGenBio. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Equities

Equities by Sector

Sectors

Thematics

Latest

Inside the mind of investors: International Biotechnology Trust

Borussia Dortmund – executive interviews

UK equities: A generational opportunity?

Audiovisual

Latest

Take on Trusts – December 2024

Vantage: Gresham House Energy Storage Fund – Navigating challenges in energy storage

IP Group – executive interview

About Edison

About Edison

Careers

BerGenBio (NO: BGBIO)

Latest Insights

BerGenBio — No surprises as bemcentinib strategy progresses

BerGenBio — Focusing in on 1L NSCLC and COVID-19

BerGenBio – executive interview

BerGenBio — Checking its course

Sector

Research

BerGenBio — AXLeration of data catalysts in 2021

BerGenBio — Progressing towards key inflection points

BerGenBio — AXLeration of data catalysts in 2021

BerGenBio — Progressing towards key inflection points

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time